Trial intelligence / Profile preview

Chidamide + azacitidine with DA or HAG for high-risk newly diagnosed AML with chromosome 7, 11, or 17 abnormalities

ChiCTR2300073732Phase 2Recruiting

Sponsor
West China Hospital of Sichuan University
Start
Apr 2023
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, open-label trial of tucidinostat and azacitidine in acute myeloid leukemia (AML) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Relapse-free survival. Started Apr 2023; status: recruiting.

02

Drugs

tucidinostatazacitidine
03

Conditions

acute myeloid leukemia (AML)

Beyond the preview

Go deeper on ChiCTR2300073732.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2300073732.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call